Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases

Annual Review of Medicine

Volumn 67, Issue , 2016, Pages 337-353

  Fragoulis, George E ^a   Siebert, Stefan ^a   Mcinnes, Iain B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

IL 23 IL 17 axis; Interleukin 17; Interleukin 23; Psoriasis; Psoriatic arthritis

Indexed keywords

BRIAKINUMAB; BRODALUMAB; GUSELKUMAB; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 23; IXEKIZUMAB; SECUKINUMAB; TILDRAKIZUMAB; USTEKINUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; APONDYLOARTHROPATHY; ARTHROPATHY; ARTICLE; CANDIDIASIS; CARDIOVASCULAR DISEASE; CROHN DISEASE; DEMYELINATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOPATHOLOGY; INFECTION; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; NEUTROPENIA; NON MELANOMA SKIN CANCER; NONHUMAN; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; METABOLISM; SPONDYLITIS, ANKYLOSING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-17; INTERLEUKIN-23; PSORIASIS; SPONDYLITIS, ANKYLOSING; USTEKINUMAB;

EID: 84954556278     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-051914-021944     Document Type: Article

References (100)

1. Johansen C, Usher PA, Kjellerup RB, et al. (2009). Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br. J. Dermatol. 160: 319-24
2. Hirota K, Duarte JH, Veldhoen M, et al. (2011). Fate mapping of IL-17-producingTcells in inflammatory responses. Nat. Immunol. 12: 255-63
3. Harrington LE, Hatton RD, Mangan PR, et al. (2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6: 1123-32
4. Gaffen SL, Jain R, Garg AV, Cua DJ. (2014). The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat. Rev. Immunol. 14: 585-600
5. Frleta M, Siebert S, McInnes IB. (2014). The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Curr. Rheumatol. Rep. 16: 414
6. Zhu S, Qian Y. (2012). IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin. Sci. 122: 487-511
7. Griffin GK, Newton G, Tarrio ML, et al. (2012). IL-17 and TNF-Alpha sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J. Immunol. 188: 6287-99
8. Suzuki E, Mellins ED, Gershwin ME, et al. (2014). The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun. Rev. 13: 496-502
9. Parham C, Chirica M, Timans J, et al. (2002). A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168: 5699-708
10. Ciofani M, Madar A, Galan C, et al. (2012). A validated regulatory network for Th17 cell specification. Cell 151: 289-303
11. Weigle N, McBane S. (2013). Psoriasis. Am. Fam. Phys. 87: 626-33
12. Elliott M, Benson J, Blank M, et al. (2009). Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann. N.Y. Acad. Sci. 1182: 97-110
13. Bowes J, Barton A. (2010). The genetics of psoriatic arthritis: lessons from genome-wide association studies. Discov. Med. 10: 177-83
14. Hueber W, Patel DD, Dryja T, et al. (2010). Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Trans. Med. 2: 52ra72
15. Rich P, Sigurgeirsson B, Thaci D, et al. (2013). Secukinumab induction and maintenance therapy in moderate-To-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimenfinding study. Br. J. Dermatol. 168: 402-11
16. Papp KA, Langley RG, Sigurgeirsson B, et al. (2013). Efficacy and safety of secukinumab in the treatment of moderate-To-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II doseranging study. Br. J. Dermatol. 168: 412-21
17. Langley RG, Elewski BE, Lebwohl M, et al. (2014). Secukinumab in plaque psoriasis-results of two phase 3 trials. N. Engl. J. Med. 371: 326-38
18. Leonardi C, Matheson R, Zachariae C, et al. (2012). Anti-interleukin-17monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366: 1190-99
19. Zhu B, Edson-Heredia E, Cameron GS, et al. (2013). Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-To-severe plaque psoriasis. Br. J. Dermatol. 169: 1337-41
20. Gordon KB, Leonardi CL, Lebwohl M, et al. (2014). A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 71: 1176-82
21. Papp KA, Leonardi C, Menter A, et al. (2012). Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366: 1181-89
22. Gordon KB, Kimball AB, Chau D, et al. (2014). Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, thePsoriasis Symptom Inventory. Br. J. Dermatol. 170: 705-15
23. Papp K, Menter A, Strober B, et al. (2015). Efficacy and safety of brodalumab in subpopulations of patients with difficult-To-Treat moderate-To-severe plaque psoriasis. J. Am. Acad. Dermatol. 72: 436-39e1
24. Papp K, Leonardi C, Menter A, et al. (2014). Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J. Am. Acad. Dermatol. 71: 1183-90e3
25. Krueger GG, Langley RG, Leonardi C, et al. (2007). A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356: 580-92
26. Leonardi CL, Kimball AB, Papp KA, et al. (2008). Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-74
27. Papp KA, Langley RG, Lebwohl M, et al. (2008). Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675-84
28. Lebwohl M, Papp K, Han C, et al. (2010). Ustekinumab improves health-related quality of life in patients with moderate-To-severe psoriasis: results from the PHOENIX 1 trial. Br. J. Dermatol. 162: 137-46
29. Reich K, Schenkel B, Zhao N, et al. (2011). Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-To-severe psoriasis: results from PHOENIX 2. J. Dermatol. Treat. 22: 337-47
30. Kimball AB, Gordon KB, Fakharzadeh S, et al. (2012). Long-Term efficacy of ustekinumab in patients with moderate-To-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br. J. Dermatol. 166: 861-72
31. Kimball AB, Papp KA, Wasfi Y, et al. (2013). Long-Term efficacy of ustekinumab in patientswithmoderateto-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J. Eur. Acad. Dermatol. Venereol. 27: 1535-45
32. Langley RG, Lebwohl M, Krueger GG, et al. (2014). Long-Term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-To-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br. J. Dermatol. 172: 1371-83
33. Paul C, Puig L, Kragballe K, et al. (2014). Transition to ustekinumab in patients with moderate-Tosevere psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). Br. J. Dermatol. 170: 425-34
34. Griffiths CE, Strober BE, van de Kerkhof P, et al. (2010). Comparison of ustekinumab and etanercept for moderate-To-severe psoriasis. N. Engl. J. Med. 362: 118-28
35. Patsatsi A, Kyriakou A, Sotiriadis D. (2013). Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. J. Dermatol. Treat. 24: 96-100
36. Rigopoulos D, Gregoriou S, Makris M, Ioannides D. (2011). Efficacy of ustekinumab in nail psoriasis and improvement in nail-Associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Dermatology 223: 325-29
37. Au SC, Goldminz AM, Kim N, et al. (2013). Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-To-severe palmoplantar psoriasis. J. Dermatol. Treat. 24: 179-87
38. Bissonnette R, Nigen S, Langley RG, et al. (2014). Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J. Eur. Acad. Dermatol. Venereol. 28: 1298-305
39. Meng Y, Dongmei L, Yanbin P, et al. (2014). Systematic review and meta-Analysis of ustekinumab for moderate to severe psoriasis. Clin. Exp. Dermatol. 39: 696-707
40. Signorovitch JE, Betts KA, Yan YS, et al. (2015). Comparative efficacy of biological treatments for moderate-To-severe psoriasis: a network meta-Analysis adjusting for cross-Trial differences in reference arm response. Br. J. Dermatol. 172: 504-12
41. Wilder EG, Patel M, Hebeler K, Menter A. (2014). Ustekinumab treatment for psoriasis in 119 patients maintained on therapy for a minimum of one year: a review. J. Drugs Dermatol. 13: 905-10
42. Sofen H, Smith S, Matheson RT, et al. (2014). Guselkumab (an IL-23-specific mAb) demonstrates clinical andmolecular response in patients with moderate-To-severe psoriasis. J. Allergy Clin. Immunol. 133: 1032-40
43. Kopp T, Riedl E, Bangert C, et al. (2015). Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 521: 222-26
44. Kimball AB, Gordon KB, Langley RG, et al. (2008). Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch. Dermatol. 144: 200-7
45. Strober BE, Crowley JJ, Yamauchi PS, et al. (2011). Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br. J. Dermatol. 165: 661-68
46. Reich K, Langley RG, Papp KA, et al. (2011). A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N. Engl. J. Med. 365: 1586-96
47. Gordon KB, Langley RG, Gottlieb AB, et al. (2012). A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-To-severe psoriasis. J. Investig. Dermatol. 132: 304-14
48. Langley RG, Papp K, Gottlieb AB, et al. (2013). Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J. Eur. Acad. Dermatol. Venereol. 27: 1252-61
49. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. (2012). IL-17 receptor and its functional significance in psoriatic arthritis. Mol. Cell. Biochem. 359: 419-29
50. Celis R, Planell N, Fernandez-Sueiro JL, et al. (2012). Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res. Ther. 14: R93
51. Felson DT, Anderson JJ, Boers M, et al. (1995). American College of Rheumatology.Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38: 727-35
52. Gottlieb A, Menter A, Mendelsohn A, et al. (2009). Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373: 633-40
53. McInnes IB, Kavanaugh A, Gottlieb AB, et al. (2013). Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382: 780-89
54. Ritchlin C, Rahman P, Kavanaugh A, et al. (2014). Efficacy and safety of the anti-IL-12/23 p40monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-Tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann. Rheum. Dis. 73: 990-99
55. Kavanaugh A, Ritchlin C, Rahman P, et al. (2014). Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebocontrolled PSUMMIT-1 and PSUMMIT-2 trials. Ann. Rheum. Dis. 73: 1000-6
56. McInnes IB, Sieper J, Braun J, et al. (2014). Efficacy and safety of secukinumab, a fully human antiinterleukin-17A monoclonal antibody, in patients withmoderate-To-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann. Rheum. Dis. 73: 349-56
57. McInnes IB MP, Kirkham B, Kavanaugh A, et al. (2014). Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis: 24-week efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study using subcutaneous dosing. Arthritis Rheumatol. 66: 3529-40
58. Mease PJMI, Kirkham B, Kavanaugh A, et al. (2014). Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheumatol. 66: 3529-40
59. Mease PJ, Genovese MC, Greenwald MW, et al. (2014). Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N. Engl. J. Med. 370: 2295-306
60. Smith JA, Colbert RA. (2014). Review: the interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol. 66: 231-41
61. Reveille JD. (2012). Genetics of spondyloarthritis-beyond the MHC. Nat. Rev. Rheumatol. 8: 296-304
62. Shen H, Goodall JC, Hill Gaston JS. (2009). Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 60: 1647-56
63. Colbert RA, Tran TM, Layh-Schmitt G. (2014). HLA-B27 misfolding and ankylosing spondylitis. Mol. Immunol. 57: 44-51
64. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. (2012). IL-23 induces spondyloarthropathy by acting on ROR-?t+ CD3+CD4-CD8-entheseal resident T cells. Nat. Med. 18: 1069-76
65. Baeten D, Baraliakos X, Braun J, et al. (2013). Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382: 1705-13
66. Poddubnyy D, Hermann KG, Callhoff J, et al. (2014). Ustekinumab for the treatment of patientswith active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).Ann. Rheum. Dis. 73: 817-23
67. Baraliakos X, Braun J, Laurent DD, et al. (2011). Interleukin-17A blockade with secukinumab reduces spinal inflammation in patients with ankylosing spondylitis as early as week 6, as detected by magnetic resonance imaging. Arthritis Rheum. 63(Suppl. 10): 2486D
68. Lubberts E, Koenders MI, Oppers-Walgreen B, et al. (2004). Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50: 650-59
69. Malfait AM, Butler DM, Presky DH, et al. (1998). Blockade of IL-12 during the induction of collageninduced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin. Exp. Immunol. 111: 377-83
70. Kotake S, Udagawa N, Takahashi N, et al. (1999). IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103: 1345-52
71. Honorati MC, Meliconi R, Pulsatelli L, et al. (2001). High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients. Rheumatology 40: 522-27
72. Shahrara S, Pickens SR, Dorfleutner A, Pope RM. (2009). IL-17 induces monocyte migration in rheumatoid arthritis. J. Immunol. 182: 3884-91
73. Melis L, Vandooren B, Kruithof E, et al. (2010). Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann. Rheum. Dis. 69: 618-23
74. Genovese MC, Durez P, Richards HB, et al. (2013). Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann. Rheum. Dis. 72: 863-69
75. Genovese MC, Durez P, Richards HB, et al. (2014). One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J. Rheumatol. 41: 414-21
76. Genovese MC, Greenwald M, Cho CS, et al. (2014). A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol. 66: 1693-704
77. Martin DA, Churchill M, Flores-Suarez L, et al. (2013). A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res. Ther. 15: R164
78. Duerr RH, Taylor KD, Brant SR, et al. (2006). A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314: 1461-63
79. Neurath MF, Fuss I, Kelsall BL, et al. (1995). Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182: 1281-90
80. Kobayashi T, Okamoto S, Hisamatsu T, et al. (2008). IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57: 1682-89
81. Hueber W, Sands BE, Lewitzky S, et al. (2012). Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebocontrolled trial. Gut 61: 1693-700
82. Colombel JF, Sendid B, Jouault T, Poulain D. (2013). Secukinumab failure in Crohn's disease: the yeast connection? Gut 62: 800-1
83. Targan SR FB, Vermeire S, Panaccione R, et al. (2012). A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn's disease. Gastroenterology 143: e26 (Abstr
84. Sandborn WJ, Feagan BG, Fedorak RN, et al. (2008). A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-To-severe Crohn's disease. Gastroenterology 135: 1130-41
85. Sandborn WJ, Gasink C, Gao LL, et al. (2012). Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367: 1519-28
86. Ringkowski S, Thomas PS, Herbert C. (2014). Interleukin-12 family cytokines and sarcoidosis. Front. Pharmacol. 5: 233
87. Puel A, Cypowyj S, Bustamante J, et al. (2011). Chronicmucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332: 65-68
88. Filipe-Santos O, Bustamante J, Chapgier A, et al. (2006). Inborn errors of IL-12/23-And IFN-gammamediated immunity: molecular, cellular, and clinical features. Semin. Immunol. 18: 347-61
89. Tsai TF, Ho V, Song M, et al. (2012). The safety of ustekinumab treatment in patients with moderateto-severe psoriasis and latent tuberculosis infection. Br. J. Dermatol. 167: 1145-52
90. Adelzadeh L, Jourabchi N, Wu JJ. (2014). The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J. Eur. Acad. Dermatol. Venereol. 28: 846-52
91. Papp KA, Griffiths CE, Gordon K, et al. (2013). Long-Term safety of ustekinumab in patients with moderate-To-severe psoriasis: final results from 5 years of follow-up. Br. J. Dermatol. 168: 844-54
92. Ryan C, Leonardi CL, Krueger JG, et al. (2011). Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-Analysis of randomized controlled trials. JAMA 306: 864-71
93. Tzellos T, Kyrgidis A, Zouboulis CC. (2013). Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a metaanalysis of randomized controlled trials. J. Eur. Acad. Dermatol. Venereol. 27: 622-27
94. Dommasch ED, Troxel AB, Gelfand JM. (2014). Counterpoint: a tale of two meta-Analyses revisited. J. Am. Acad. Dermatol. 70: 381-83
95. Gottlieb AB, Kalb RE, Langley RG, et al. (2014). Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J. Drugs Dermatol. 13: 1441-48
96. Reich K, Langley RG, Lebwohl M, et al. (2011). Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br. J. Dermatol. 164: 862-72
97. Fischer JA, Hueber AJ, Wilson S, et al. (2015). Combined inhibition of tumor necrosis factor alpha and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol. 67: 51-62
98. Solt LA, Kumar N, Nuhant P, et al. (2011). Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 472: 491-94
99. Mease PJ. (2015). Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr. Opin. Rheumatol. 27: 127-33
100. Patel DD, Lee DM, Kolbinger F, Antoni C. (2013). Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann. Rheum. Dis. 72(Suppl. 2): ii116-23